Strengths
- CB Insights lists Wheel as a unicorn at $1.01B.
- Wheel's core product positioning is supported by company-owned public product evidence.
- Public compliance/security or governance claims are visible but require audit/report validation.
Diligence report
Wheel
Wheel Startup Diligence Research Report
Public evidence supports a credible Healthcare and Life Sciences / virtual care infrastructure platform with real product and market signals; the investment question is whether private financial quality, customer concentration, retention and compliance evidence justify the public unicorn valuation.
Company profile
Wheel Startup Diligence Research Report
Wheel is an eligible public-source diligence target: active private-company evidence and CB Insights unicorn metadata support a latest known valuation of $1.01B, while key economics remain private.
- Website
- www.wheel.com
- Sector
- Healthcare and Life Sciences / virtual care infrastructure
- Geography
- United States; Austin, Texas
- Stage
- Private unicorn; growth-stage virtual care platform
- Known aliases
- Wheel Health, Wheel Horizon, Wheel Medical Group
- Report version
- 1.0
- Timezone
- America/Chicago
Executive summary
Risks
- Healthcare regulatory and 50-state clinical-operations exposure is central to the model
- Provider network economics, credentialing quality and customer concentration are not public
- The $1.01B valuation and $216M+ funding history require private financing documents
Gaps
- Audited financial statements, revenue by product/channel/geography, backlog and AR aging
- Cap table, preference stack, options/warrants/debt and 409A history
- ARR/revenue by customer, churn, retention and top-account contracts
- SOC/audit reports, regulatory correspondence, DPAs/BAAs and insurance
Risk register
R-001: Financing and valuation terms are not public
Public sources support $1.01B unicorn status, but cap table, liquidation preferences, option pool, debt and current 409A are private.
Diligence request: Request financing documents, cap table, 409A history, investor rights and debt/SAFE schedules.
R-006: Legal, privacy and regulatory exposure requires counsel review
Virtual care operations, clinician network, HIPAA, state telehealth and pharma-specific compliance are central to Wheel.
Diligence request: Request SOC/HITRUST/ISO reports, privacy/regulatory correspondence, DPAs/BAAs, insurance and counsel memo.
R-002: Revenue quality and customer concentration cannot be verified publicly
Customer names, usage or aggregate scale do not disclose ARR by account, retention, churn, backlog or gross margin.
Diligence request: Request customer-level ARR, cohort retention, renewal pipeline, backlog and top-customer contracts.
R-008: Public-source evidence cannot verify profitability or runway
No audited financials, cash balance, burn, debt, margin or runway schedule was public.
Diligence request: Request monthly financial model, bank statements, runway scenarios, budget variance and debt/off-balance-sheet schedules.
R-003: Strategic partner and supplier concentration may be material
Public relationships include Wheel Medical Group, Lab and pharmacy integrations, 50-state clinician network, but dependency economics and termination rights are private.
Diligence request: Request partner/supplier contracts, SLAs, termination provisions and revenue contribution.
R-004: Competitive pressure may compress pricing and retention
The virtual care compliance and clinical operations category has credible incumbents and venture-backed alternatives.
Diligence request: Run win/loss calls, pipeline reviews, discounting analysis and churn reason-code analysis.
R-005: Product roadmap execution and technical claims need telemetry
Public product and R&D signals are not enough to validate uptime, performance, model/AI quality, clinical quality or engineering cost.
Diligence request: Request roadmap, release history, product usage, incident reports, QA metrics and engineering-capacity plan.
R-007: Management, headcount and retention data are incomplete
Public leadership/headcount signals do not disclose attrition, compensation, incentive plans or key-person dependencies.
Diligence request: Request org chart, payroll roster, attrition, compensation, equity plan and key employment agreements.
01Financial Information
Wheel has public unicorn/financing evidence but private financial statements, projections, cap table and debt schedules are required for investment-grade diligence.
I.A Annual and quarterly financial information for the past three years
partially verified confidence: medium
No audited historical financial statements, management accounts, revenue by product/channel/geography, backlog or AR aging were public for Wheel; public evidence is limited to financing and scale signals.
Evidence gaps
- Private data-room records are required to fully answer this checklist section.
Hidden risks
- Investor preference stack, debt, burn and revenue quality can materially change valuation despite public unicorn status.
Follow-up questions
- Provide source records and owner interview for I.A: Annual and quarterly financial information for the past three years.
| metric | public signal | verification status | diligence request |
|---|---|---|---|
| Audited financial statements | Not disclosed in public sources | not_publicly_verifiable | Request audited financials, monthly management accounts, balance sheet, cash-flow statement and accounting policies. |
| ARR / revenue / gross margin | Funding and platform scope disclosed, revenue not disclosed | not_publicly_verifiable | Request revenue by product, channel, geography, cohort, gross margin and backlog. |
| Cash runway and debt | No debt schedule or cash balance found in public sources | not_publicly_verifiable | Request cash balance, burn, debt instruments, credit lines and scenario plan. |
I.B Financial Projections
inconclusive confidence: medium
No public financial projections were found; diligence should test growth drivers, pricing assumptions, runway, foreign-operations exposure and financing assumptions against actual performance.
Evidence gaps
- Private data-room records are required to fully answer this checklist section.
Hidden risks
- Investor preference stack, debt, burn and revenue quality can materially change valuation despite public unicorn status.
Follow-up questions
- Provide source records and owner interview for I.B: Financial Projections.
I.C Capital Structure
inconclusive confidence: medium
The public record supports a unicorn financing signal, but ownership, options, warrants, debt, preferences and off-balance-sheet obligations are private.
Evidence gaps
- Private data-room records are required to fully answer this checklist section.
Hidden risks
- Investor preference stack, debt, burn and revenue quality can materially change valuation despite public unicorn status.
Follow-up questions
- Provide source records and owner interview for I.C: Capital Structure.
I.D Other financial information
partially verified confidence: medium
Wheel's latest known valuation signal is $1.01B; reconcile CB/company evidence to financing documents and current 409A.
Evidence gaps
- Private data-room records are required to fully answer this checklist section.
Hidden risks
- Investor preference stack, debt, burn and revenue quality can materially change valuation despite public unicorn status.
Follow-up questions
- Provide source records and owner interview for I.D: Other financial information.
| date | round | lead or participants | amount | post money or valuation | source |
|---|---|---|---|---|---|
| 2022-01-19 | Unicorn / Series C signal | CB row: Silverton Partners, Tusk Ventures, CRV; Wheel page links Series C announcement | $216M+ total funding disclosed; round amount not confirmed in accessible source | $1.01B | Public company/CB evidence |
| Current public status | Private unicorn status check | Active company website and CB Insights private-company unicorn list | Not publicly verifiable | $1.01B | CB Insights plus active company-owned pages |
02Products
Public product pages support Wheel's category positioning, while pricing, usage and profitability by SKU remain private.
II.A Description of each product
partially verified confidence: medium
Public sources describe Wheel's products, but SKU-level adoption, margins, pricing and technical performance require private validation.
Evidence gaps
- Private data-room records are required to fully answer this checklist section.
Hidden risks
- Public evidence may overstate traction because customer economics, renewal health and operating metrics are private.
Follow-up questions
- Provide source records and owner interview for II.A: Description of each product.
| product | audience | key features | verification status |
|---|---|---|---|
| Wheel Horizon | Digital health, pharma, health plans, retailers and pharmacies | End-to-end virtual care infrastructure for launching and scaling care programs | verified |
| Care enablement platform | Care program operators | Intake, scheduling, visit modalities, messaging, remote monitoring and EMR workflows | partially_verified |
| Integrated clinical operations | Organizations needing care delivery services | Care delivery, quality assurance, clinical governance, credentialing and oversight | partially_verified |
| Data intelligence and ecosystem integrations | Program managers and clinical leaders | Dashboards, program reporting, behavioral/clinical insights, lab and pharmacy integration | partially_verified |
| item | public signal | risk or gap | verification status |
|---|---|---|---|
| Published pricing | No reliable public price list captured in this sweep. | Gross margin, discounting and sales-cycle economics remain private. | not_publicly_verifiable |
| Enterprise packaging | Product pages indicate enterprise-oriented platform capabilities. | Need SKU-level bookings, attach rates, professional services and renewal terms. | partially_verified |
03Customer Information
Public customer/partner proof exists, but customer concentration and supplier economics are private.
III.A Top customers by application
not publicly verifiable confidence: low
Public customer or customer-scale signals exist, but top-customer ARR and application-level revenue are not public.
Evidence gaps
- Private data-room records are required to fully answer this checklist section.
Hidden risks
- Public evidence may overstate traction because customer economics, renewal health and operating metrics are private.
Follow-up questions
- Provide source records and owner interview for III.A: Top customers by application.
| customer or segment | public evidence | use case | verification status |
|---|---|---|---|
| GoodRx Care | Product page quotes GoodRx Care leader saying Wheel provided technology and clinicians for several years | Strategic customer/partner proof point | partially_verified |
| Leading consumer and digital health brands | Wheel about page says it powers virtual care programs of leading consumer and digital health brands | Aggregate customer signal; names and economics not public | partially_verified |
| Pharma/life sciences, health plans, retailers/pharmacies | Wheel navigation/product pages identify served industries | Target segments and go-to-market focus | partially_verified |
III.B Strategic relationships
partially verified confidence: medium
Public strategic relationships/supplier dependencies are visible, but contract economics and revenue contribution are private.
Evidence gaps
- Private data-room records are required to fully answer this checklist section.
Hidden risks
- Public evidence may overstate traction because customer economics, renewal health and operating metrics are private.
Follow-up questions
- Provide source records and owner interview for III.B: Strategic relationships.
| partner or supplier | nature | diligence caveat | verification status |
|---|---|---|---|
| Wheel Medical Group | Clinical governance and delivery layer named on Horizon page | Affiliated/operating clinical entity requiring legal and regulatory review | partially_verified |
| Lab and pharmacy integrations | Horizon page says platform connects core services from lab ordering to pharmacy integration | Supplier dependency to diligence privately | partially_verified |
| 50-state clinician network | Company-disclosed clinician network | Operational supply dependency and credentialing risk | partially_verified |
III.C Revenue by customer
not publicly verifiable confidence: low
Revenue by customer and any 5%+ concentration are not publicly verifiable.
Evidence gaps
- Private data-room records are required to fully answer this checklist section.
Hidden risks
- Public evidence may overstate traction because customer economics, renewal health and operating metrics are private.
Follow-up questions
- Provide source records and owner interview for III.C: Revenue by customer.
III.D Significant relationships severed within the last two years
inconclusive confidence: medium
No public schedule of severed major customer, partner or supplier relationships was found.
Evidence gaps
- Private data-room records are required to fully answer this checklist section.
Hidden risks
- Public evidence may overstate traction because customer economics, renewal health and operating metrics are private.
Follow-up questions
- Provide source records and owner interview for III.D: Significant relationships severed within the last two years.
III.E Top suppliers
not publicly verifiable confidence: low
Top supplier spend and critical operational dependencies are not publicly disclosed; visible dependencies should be contract-reviewed.
Evidence gaps
- Private data-room records are required to fully answer this checklist section.
Hidden risks
- Public evidence may overstate traction because customer economics, renewal health and operating metrics are private.
Follow-up questions
- Provide source records and owner interview for III.E: Top suppliers.
04Competition
Competitive differentiation is plausible from public positioning but must be tested through win/loss and customer diligence.
IV.A Competitive landscape by market segment
partially verified confidence: medium
Wheel operates in a competitive virtual care compliance and clinical operations market; public positioning should be tested with win/loss and customer calls.
Evidence gaps
- Private data-room records are required to fully answer this checklist section.
Hidden risks
- Public evidence may overstate traction because customer economics, renewal health and operating metrics are private.
Follow-up questions
- Provide source records and owner interview for IV.A: Competitive landscape by market segment.
| competitor | product overlap | differentiator to test | source type |
|---|---|---|---|
| Teladoc Health | Scaled virtual care provider/platform | Public incumbent with consumer/provider relationships | Analyst market mapping from public positioning; validate with customer references. |
| Amwell | Telehealth infrastructure and provider network | Enterprise telehealth competitor | Analyst market mapping from public positioning; validate with customer references. |
| Included Health | Navigation, virtual care and employer/payer relationships | Customer-account overlap in digital health | Analyst market mapping from public positioning; validate with customer references. |
| Thirty Madison / Ro | Condition-specific digital health operators | Potential verticalized competitors/customers/substitutes | Analyst market mapping from public positioning; validate with customer references. |
| axis | target position | diligence test | risk |
|---|---|---|---|
| Product breadth | Wheel Horizon; Care enablement platform; Integrated clinical operations; Data intelligence and ecosystem integrations | Obtain roadmap, usage telemetry, expansion ARR and customer proof points. | medium |
| Distribution and ecosystem | Wheel Medical Group; Lab and pharmacy integrations; 50-state clinician network | Review partner contracts, referral/co-sell terms and supplier dependencies. | medium |
| Pricing pressure | No full public pricing or discount schedules disclosed. | Analyze win/loss, discounting, renewal concessions and gross retention. | high |
05Marketing, Sales, and Distribution
GTM appears enterprise/platform-led with public proof points, but sales productivity and marketing budget efficiency are not public.
V.A Strategy and implementation
partially verified confidence: medium
The public GTM motion appears enterprise/platform-led, but channel mix, CAC and sales productivity are private.
Evidence gaps
- Private data-room records are required to fully answer this checklist section.
Hidden risks
- Public evidence may overstate traction because customer economics, renewal health and operating metrics are private.
Follow-up questions
- Provide source records and owner interview for V.A: Strategy and implementation.
| channel | public evidence | gap | verification status |
|---|---|---|---|
| Enterprise direct sales | Company pages emphasize enterprise platform capabilities and talk-to-sales/contact-sales motions. | Pipeline, quota, sales-cycle and CAC not public. | partially_verified |
| Partner/ecosystem | Wheel Medical Group; Lab and pharmacy integrations; 50-state clinician network | Partner contribution, revenue share and channel conflict not public. | partially_verified |
V.B Major Customers
inconclusive confidence: medium
Public customer logos or aggregates support market proof, but relationship depth, renewal health and pipeline are private.
Evidence gaps
- Private data-room records are required to fully answer this checklist section.
Hidden risks
- Public evidence may overstate traction because customer economics, renewal health and operating metrics are private.
Follow-up questions
- Provide source records and owner interview for V.B: Major Customers.
V.C Principal avenues for generating new business
partially verified confidence: medium
Principal new-business avenues appear to include direct enterprise sales, public customer proof and partner ecosystem activity.
Evidence gaps
- Private data-room records are required to fully answer this checklist section.
Hidden risks
- Public evidence may overstate traction because customer economics, renewal health and operating metrics are private.
Follow-up questions
- Provide source records and owner interview for V.C: Principal avenues for generating new business.
| signal | evidence | diligence gap | risk level |
|---|---|---|---|
| Customer proof | GoodRx Care; Leading consumer and digital health brands; Pharma/life sciences, health plans, retailers/pharmacies | Request customer references, signed contracts and logo-use permissions. | medium |
| Investor/valuation halo | $1.01B latest public unicorn valuation signal. | Request financing documents, preferences and investor communications. | high |
| Product differentiation | Wheel Horizon; Care enablement platform | Benchmark adoption and win/loss by segment. | medium |
V.D Sales force productivity model
not publicly verifiable confidence: low
Sales force productivity, quotas, ramp, compensation and sales cycle were not publicly disclosed.
Evidence gaps
- Private data-room records are required to fully answer this checklist section.
Hidden risks
- Public evidence may overstate traction because customer economics, renewal health and operating metrics are private.
Follow-up questions
- Provide source records and owner interview for V.D: Sales force productivity model.
V.E Ability to implement marketing plan with current and projected budgets
inconclusive confidence: medium
Marketing budget sufficiency cannot be verified without budget, pipeline conversion and CAC/LTV records.
Evidence gaps
- Private data-room records are required to fully answer this checklist section.
Hidden risks
- Public evidence may overstate traction because customer economics, renewal health and operating metrics are private.
Follow-up questions
- Provide source records and owner interview for V.E: Ability to implement marketing plan with current and projected budgets.
06Research and Development
Public roadmap/R&D signals exist but need product telemetry, engineering plan and security/quality validation.
VI.A Description of R&D organization
partially verified confidence: medium
Public R&D/personnel signals are partial; request engineering/product org chart and capacity plan.
Evidence gaps
- Private data-room records are required to fully answer this checklist section.
Hidden risks
- Public evidence may overstate traction because customer economics, renewal health and operating metrics are private.
Follow-up questions
- Provide source records and owner interview for VI.A: Description of R&D organization.
| name or role | public signal | diligence request | verification status |
|---|---|---|---|
| Michelle Davey | Founder / CEO signal - Wheel about page identifies Michelle Davey as founder and links to a CEO note | Request full R&D/product org chart, tenure, attrition, compensation and invention-assignment records. | partially_verified |
| Griffin Mulcahey | Founder - Wheel about page identifies Griffin Mulcahey as founder | Request full R&D/product org chart, tenure, attrition, compensation and invention-assignment records. | partially_verified |
| Other senior leaders | Not fully enumerated in accessible public-source sweep - Request org chart and management biographies | Request full R&D/product org chart, tenure, attrition, compensation and invention-assignment records. | not_publicly_verifiable |
VI.B New Product Pipeline
partially verified confidence: medium
Public product-roadmap signals exist, but delivery timing, costs and dependencies are private.
Evidence gaps
- Private data-room records are required to fully answer this checklist section.
Hidden risks
- Public evidence may overstate traction because customer economics, renewal health and operating metrics are private.
Follow-up questions
- Provide source records and owner interview for VI.B: New Product Pipeline.
| project | public evidence | expected or gap | verification status |
|---|---|---|---|
| Care enablement platform | Intake, scheduling, visit modalities, messaging, remote monitoring and EMR workflows | Roadmap, release adoption and engineering cost require private validation. | partially_verified |
| Integrated clinical operations | Care delivery, quality assurance, clinical governance, credentialing and oversight | Roadmap, release adoption and engineering cost require private validation. | partially_verified |
| Data intelligence and ecosystem integrations | Dashboards, program reporting, behavioral/clinical insights, lab and pharmacy integration | Roadmap, release adoption and engineering cost require private validation. | partially_verified |
07Management and Personnel
Public management/headcount information is incomplete and needs HR data-room review.
VII.A Organization Chart
not publicly verifiable confidence: low
A complete organization chart was not publicly available.
Evidence gaps
- Private data-room records are required to fully answer this checklist section.
Hidden risks
- Public evidence may overstate traction because customer economics, renewal health and operating metrics are private.
Follow-up questions
- Provide source records and owner interview for VII.A: Organization Chart.
VII.B Historical and projected headcount by function and location
not publicly verifiable confidence: low
Only sparse headcount anchors were public; historical/projected headcount by function and location requires payroll data.
Evidence gaps
- Private data-room records are required to fully answer this checklist section.
Hidden risks
- Public evidence may overstate traction because customer economics, renewal health and operating metrics are private.
Follow-up questions
- Provide source records and owner interview for VII.B: Historical and projected headcount by function and location.
| date or source | headcount signal | caveat | verification status |
|---|---|---|---|
| The Org profile | 51-200 employees | Third-party profile estimate; request payroll/headcount export | partially_verified |
| Private request | Historical and projected headcount by function/location not public | Request payroll, hiring plan, attrition and contractor schedules. | not_publicly_verifiable |
VII.C Senior management biographies
partially verified confidence: medium
Some senior management signals are public; full biographies, tenure and key-person dependencies need validation.
Evidence gaps
- Private data-room records are required to fully answer this checklist section.
Hidden risks
- Public evidence may overstate traction because customer economics, renewal health and operating metrics are private.
Follow-up questions
- Provide source records and owner interview for VII.C: Senior management biographies.
| name | role | public evidence | follow up |
|---|---|---|---|
| Michelle Davey | Founder / CEO signal | Wheel about page identifies Michelle Davey as founder and links to a CEO note | Verify full biography, tenure, employment agreement and incentive ownership. |
| Griffin Mulcahey | Founder | Wheel about page identifies Griffin Mulcahey as founder | Verify full biography, tenure, employment agreement and incentive ownership. |
| Other senior leaders | Not fully enumerated in accessible public-source sweep | Request org chart and management biographies | Verify full biography, tenure, employment agreement and incentive ownership. |
VII.D Compensation arrangements
not publicly verifiable confidence: low
Employment agreements, benefits and compensation arrangements were not public.
Evidence gaps
- Private data-room records are required to fully answer this checklist section.
Hidden risks
- Public evidence may overstate traction because customer economics, renewal health and operating metrics are private.
Follow-up questions
- Provide source records and owner interview for VII.D: Compensation arrangements.
VII.E Incentive stock plans
not publicly verifiable confidence: low
Incentive stock plans and option grants were not publicly verifiable.
Evidence gaps
- Private data-room records are required to fully answer this checklist section.
Hidden risks
- Public evidence may overstate traction because customer economics, renewal health and operating metrics are private.
Follow-up questions
- Provide source records and owner interview for VII.E: Incentive stock plans.
VII.F Significant employee relations problems, past or present
inconclusive confidence: medium
No public schedule of employee relations matters was found; do not infer absence without HR/counsel records.
Evidence gaps
- Private data-room records are required to fully answer this checklist section.
Hidden risks
- Public evidence may overstate traction because customer economics, renewal health and operating metrics are private.
Follow-up questions
- Provide source records and owner interview for VII.F: Significant employee relations problems, past or present.
VII.G Personnel Turnover
not publicly verifiable confidence: low
Turnover, retention and benefits data were not public.
Evidence gaps
- Private data-room records are required to fully answer this checklist section.
Hidden risks
- Public evidence may overstate traction because customer economics, renewal health and operating metrics are private.
Follow-up questions
- Provide source records and owner interview for VII.G: Personnel Turnover.
08Legal and Related Matters
Public compliance/security posture is material, but legal, IP, insurance and contract schedules require counsel review.
VIII.A Pending lawsuits against the Company
partially verified confidence: medium
No public litigation schedule against the company was compiled; counsel docket review is required.
Evidence gaps
- Private data-room records are required to fully answer this checklist section.
Hidden risks
- Legal, privacy, IP or insurance exclusions may exist even when no public issue is found.
Follow-up questions
- Provide source records and owner interview for VIII.A: Pending lawsuits against the Company.
| matter type | public result | diligence request | verification status |
|---|---|---|---|
| Pending lawsuits against company | No docket search was completed in this public-source pass. | Counsel to provide litigation schedule and docket search in all material jurisdictions. | not_publicly_verifiable |
| Lawsuits initiated by company | No public source in this pass enumerated company-initiated litigation. | Counsel to provide claims, demands and pending/settled litigation list. | not_publicly_verifiable |
| Insurance and material exposures | Insurance schedules were not public. | Request cyber, E&O, D&O, employment, healthcare/professional liability where applicable, and exclusions. | not_publicly_verifiable |
VIII.B Pending lawsuits initiated by Company
inconclusive confidence: medium
No public schedule of company-initiated litigation was compiled; counsel docket review is required.
Evidence gaps
- Private data-room records are required to fully answer this checklist section.
Hidden risks
- Legal, privacy, IP or insurance exclusions may exist even when no public issue is found.
Follow-up questions
- Provide source records and owner interview for VIII.B: Pending lawsuits initiated by Company.
VIII.C Environmental and employee safety issues and liabilities
inconclusive confidence: medium
Environmental/safety exposure appears limited to sector-specific operations in public sources, but formal review is needed.
Evidence gaps
- Private data-room records are required to fully answer this checklist section.
Hidden risks
- Legal, privacy, IP or insurance exclusions may exist even when no public issue is found.
Follow-up questions
- Provide source records and owner interview for VIII.C: Environmental and employee safety issues and liabilities.
VIII.D Material patents, copyrights, licenses, and trademarks
partially verified confidence: medium
Public compliance and product/IP signals exist, but full IP ownership and licenses are private.
Evidence gaps
- Private data-room records are required to fully answer this checklist section.
Hidden risks
- Legal, privacy, IP or insurance exclusions may exist even when no public issue is found.
Follow-up questions
- Provide source records and owner interview for VIII.D: Material patents, copyrights, licenses, and trademarks.
| item | public signal | risk or gap | verification status |
|---|---|---|---|
| Regulatory/security posture | Wheel states Horizon is HIPAA, SOC 2 and HITRUST aligned; compliance page says SOC 2 certified and HIPAA-compliant with 50-state legal/compliance tracking. | Request SOC reports, pen tests, insurance, DPAs/BAAs and regulatory correspondence. | partially_verified |
| IP ownership / patents / trademarks | No comprehensive public IP schedule compiled in this sweep. | Request patent/trademark list, open-source inventory, invention assignments and third-party licenses. | not_publicly_verifiable |
| Material contracts | Wheel Medical Group; Lab and pharmacy integrations; 50-state clinician network | Request customer, supplier, reseller, clinical/technology partner and data-processing contracts. | not_publicly_verifiable |
VIII.E Insurance coverage and material exposures
not publicly verifiable confidence: low
Insurance coverage and exclusions were not public.
Evidence gaps
- Private data-room records are required to fully answer this checklist section.
Hidden risks
- Legal, privacy, IP or insurance exclusions may exist even when no public issue is found.
Follow-up questions
- Provide source records and owner interview for VIII.E: Insurance coverage and material exposures.
VIII.F Material contracts
not publicly verifiable confidence: low
Material customer, supplier, partner and data-processing contracts are not public.
Evidence gaps
- Private data-room records are required to fully answer this checklist section.
Hidden risks
- Legal, privacy, IP or insurance exclusions may exist even when no public issue is found.
Follow-up questions
- Provide source records and owner interview for VIII.F: Material contracts.
VIII.G Regulatory agency problems
partially verified confidence: medium
Public compliance posture is material; request independent audit reports, regulatory correspondence and counsel review.
Evidence gaps
- Private data-room records are required to fully answer this checklist section.
Hidden risks
- Legal, privacy, IP or insurance exclusions may exist even when no public issue is found.
Follow-up questions
- Provide source records and owner interview for VIII.G: Regulatory agency problems.
Evidence
| ID | Claim | Status | Sources |
|---|---|---|---|
| EC-001 | Wheel appears on a public CB Insights unicorn list at $1.01B. | partially verified high | SRC-001 |
| EC-002 | Wheel's latest known financing/valuation signal is public, but full terms are private. | partially verified medium | SRC-001SRC-002 |
| EC-003 | Wheel's product positioning is publicly described. | verified high | SRC-003 |
| EC-004 | Wheel discloses customer/market scale or customer examples, but revenue concentration is private. | partially verified medium | SRC-002 |
| EC-005 | Wheel has public R&D/product-roadmap signals. | partially verified medium | SRC-003 |
| EC-006 | Wheel's public compliance/security posture is material to diligence. | partially verified medium | SRC-004 |
| EC-007 | Wheel's public management/headcount signal is incomplete. | partially verified medium | SRC-006 |
| EC-008 | Wheel's strategic relationships and supplier dependencies require private contract review. | partially verified medium | SRC-003 |
| EC-009 | Wheel's audited financials, ARR, churn, cap table, employee agreements and legal schedules are not publicly verifiable. | not publicly verifiable high | SRC-001 |
| EC-010 | Wheel competes in a crowded category where public differentiation needs customer and win/loss validation. | inconclusive medium | SRC-003 |
| ID | Publisher | Title | Accessed |
|---|---|---|---|
| SRC-001 | CB Insights | The Complete List Of Unicorn Companies | 2026-06-09 |
| SRC-002 | Wheel | Wheel about page | 2026-06-09 |
| SRC-003 | Wheel | Horizon Virtual Care Platform | 2026-06-09 |
| SRC-004 | Wheel | Wheel SOC 2 + HIPAA-compliant virtual care | 2026-06-09 |
| SRC-005 | Wheel | Wheel homepage | 2026-06-09 |
| SRC-006 | The Org | Wheel | The Org | 2026-06-09 |
| SRC-007 | Medium | Wheel Series C announcement on Medium (blocked by security verification) | 2026-06-09 |
Disclaimer
This report is a public-evidence diligence snapshot, not investment advice. Important financial, legal, technical, and contractual facts remain non-public and should be verified directly with management and primary documents before any investment decision.